Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome — LOLAbiome  

Cirrhosis Clinical Trial

Official title: An Observational Study on the Effect of L-ornithine-L-aspertate (LOLA) on the Flavonifractor Abundance in the Gut Microbiome in Liver Cirrhosis

Status Recruiting

Clinical Trial Summary

Study to test the effect of the drug "L-ornithine.L-aspertate" (LOLA) on microorganisms in the digestive tract in patients with liver cirrhosis (damage of the liver due to liver disease)

Clinical Trial Description

Liver cirrhosis is associated with gut microbiome dysbiosis, which may drive intestinal inflammation, gut barrier dysfunction and the development of complications. LOLA is a well-established drug against elevated ammonia levels that contribute to hepatic encephalopathy and sarcopenia. In a recent retrospective study, LOLA has been shown to improve gut microbiome dysbiosis.

In this study we aim to investigate whether LOLA therapy over three months in patients with liver cirrhosis (irrespective of the etiology) and covert or overt hepatic encephalopathy (HE) leads to an improvement in gut microbiome dysbiosis, as well as markers of gut permeability, inflammation, muscle function and ammonia levels. ;

Related Conditions & MeSH terms

• Cirrhosis
• Fibrosis
• Liver Cirrhosis

• NCT number: NCT05737030
• Study type: Interventional
• Source: Medical University of Graz
• Contact: Angela Horvath
• Phone: 0043 316 385
• Email: angela.horvath@cbmed.at
• Status: Recruiting
• Phase: Phase 4
• Start date: February 6, 2023
• Completion date: December 2025